| HOST SPECIES: | Rabbit |
| SPECIES REACTIVITY: | Human, Mouse, Rat |
| IMMUNOGEN: | DR5 antibody was raised against a peptide corresponding to 20 amino acids near the carboxy terminus of human DR5 precursor. The immunogen is located within the last 50 amino acids of DR5. |
| TESTED APPLICATIONS: | ELISA, ICC, IF, IHC-P, WB |
| APPLICATIONS: | WB: 0.5-1 μg/mL; ICC: 5 μg /mL; IHC-P: 5 μg/mL; IF: 10 μg/mL. Antibody validated: Western Blot in human and mouse samples; Immunohistochemistry in human and mouse samples; Immunocytochemistry in human samples and Immunofluorescence in human and mouse samples. All other applications and species not yet tested. |
| SPECIFICITY: | Antibody has no cross reaction to DR4. |
| POSITIVE CONTROL: | 1) Cat. No. 1201 - HeLa Cell Lysate |
| 2) Cat. No. 1204 - K562 Cell Lysate | |
| 3) Cat. No. 17-001 - HeLa Cell Slide | |
| 4) Cat. No. 1206 – MOLT4 Cell lysate | |
| PREDICTED MOLECULAR WEIGHT: | Predicted: 48kD and 45kD Observed: 48kD and 45kD |
Specifications| VALIDATION: | KO Validation (Figure 7) shows DR5 expression detected by anti-DR5 antibodies (2019) was disrupted in DR5 KO HCT116 cells. KD validation (Figure 8): Anti-DR5 antibody (2019) specificity was further verified by DR5 specific knockdown. DR5 signal in MB231 cells transfected with DR5 siRNAs was disrupted in comparison with that in cells transfected with control siRNAs. Regulated expression validation (Figure 7,10): DR5 expression detected by anit-DR5 antibodies (2019) was up-regulated by carfilzomib treatment and was down-regulated by treatment with two or more cytokines. |
| ISOFORMS: | Human DR5 has 3 isoforms, including isoform L (440aa, 48kD), isoform S (411aa, 45kD) and isoform 3 (118aa, 13kD). Mouse DR5 has 1 isoform (381aa, 42kD), and Rat DR5 also has 1 isoform (336aa, 37kD). 2019 can detect two human isoforms and can also detect mouse and rat isoforms. |
| PURIFICATION: | DR5 Antibody is affinity chromatography purified via peptide column. |
| CLONALITY: | Polyclonal |
| ISOTYPE: | IgG |
| CONJUGATE: | Unconjugated |
| PHYSICAL STATE: | Liquid |
| BUFFER: | DR5 Antibody is supplied in PBS containing 0.02% sodium azide. |
| CONCENTRATION: | batch dependent |
| STORAGE CONDITIONS: | DR5 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures. |
| OFFICIAL SYMBOL: | TNFRSF10B |
| ALTERNATE NAMES: | DR5 Antibody: DR5, CD262, KILLER, TRICK2, TRICKB, ZTNFR9, TRAILR2, TRICK2A, TRICK2B, TRAIL-R2, KILLER/DR5, DR5, UNQ160/PRO186, Tumor necrosis factor receptor superfamily member 10B, Death receptor 5, TRAIL receptor 2 |
| ACCESSION NO.: | AF012535 |
| PROTEIN GI NO.: | 2338419 |
| GENE ID: | 8795 |
| USER NOTE: | Optimal dilutions for each application to be determined by the researcher. |
| BACKGROUND: | DR5 Antibody: Apoptosis is induced by certain cytokines including TNF and Fas ligand in the TNF family through their death domain containing receptors. TRAIL/Apo2L is a new member of the TNF family. DR4 was recently identified as the receptor for TRAIL. A novel death domain containing receptor for TRAIL was more recently identified and designated DR5, Apo2, TRAIL-R2, TRICK2, or KILLER by several groups independently. Like DR4, DR5 transcript is widely expressed in normal tissues and in many types of tumor cells. DR5 binds to TRAIL and mediates TRAIL induced cell death. Overexpression of DR5 induces apoptosis and activates NF-κB. |
| REFERENCES: | 1) Pan et al. Science 1997;277:815-8. | 2) Sheridan et al. Science 1997;277:818-21. | 3) Walczak et al. EMBO J 1997;16:5386-97. | 4) MacFarlane et al. J Biol Chem 1997;272:25417-20 |
| CITATIONS: | 1)Han et al. The novel proteasome inhibitor carfilzomib activates and enhances extrinsic apoptosiS involving stabilization of death receptor 5. Oncotarget. 2015;6(19):17532-42. PMID: 26009898 |
| 2)Rahman et al. TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype. Breast Cancer Res Treat. 2009;113(2):217-30. doi:10.1007/s10549-008-9924-5. Epub 2008.PMID: 18266105 | |
| 3)Devetzi et al. Death receptor 5 (DR5) and a 5-gene apoptotic biomarker panel with significant differential diagnostic potential in colorectal cancer. Sci Rep. 2016 ;6:36532. PMID: 27827395 | |
| 4)Bretz et al.Inflammatory cytokine regulation of TRAIL-mediated apoptosis in thyroid epithelial cells. Cell Death Differ. 2002;9(3):274-86.PMID: 11859410 | |
| 5)Candolfi et al. Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity. Clin Cancer Res. 2009;15(13):4401-14. doi: 10.1158/1078-0432.CCR-09-0155. PMID: 19570774 | |
| 6)Malhi et al. Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity. Gut. 2007;56(8):1124-31. PMID: 17470478 | |
| 7)Razumilava et al. miR-25 targets TNF-related apoptosis inducing ligand (TRAIL) death receptor-4 and promotes apoptosis resistance in cholangiocarcinoma. Hepatology. 2012;55(2):465-75.PMID: 21953056 | |
| 8)Koyama et al. Histone deacetylase inhibitors and 15-deoxy-Delta12,14-prostaglandin J2 synergistically induce apoptosis. Clin Cancer Res. 2010;16(8):2320-32. PMID: 20371690 | |
| 9)Kang et al. Drozitumab, a human antibody to death receptor 5, has potent antitumor activity against rhabdomyosarcoma with the expression of caspase-8 predictive of response. Clin Cancer Res. 2011;17(10):3181-92. doi: 10.1158/1078-0432.CCR-10-2874. Epub 2011.PMID: 21385927 | |
| 10)Gupta et al. Nimbolide, a limonoid triterpene, inhibits growth of human colorectal cancer xenografts by suppressing the proinflammatory microenvironment. Clin Cancer Res. 2013;19(16):4465-76. PMID: 23766363 | |
| 11)Yuan et al. PARP-1 regulates resistance of pancreatic cancer to TRAIL therapy. Clin Cancer Res. 2013;19(17):4750-9.PMID: 23833311 | |
| 12)Zhao et al. mTOR complex 2 is involved in regulation of Cbl-dependent c-FLIP degradation and sensitivity of TRAIL-induced apoptosis. Cancer Res. 2013;73(6):1946-57. PMID: 23319802 | |
| 13)Dhandapani et al. Retinoic acid enhances TRAIL-induced apoptosis in cancer cells by upregulating TRAIL receptor 1 expression. Cancer Res. 2011;71(15):5245-54. PMID: 21685476 | |
| 14)Sun et al. Identification of an antiapoptotic protein complex at death receptors. Cell Death Differ. 2008;15(12):1887-900. PMID: 18846110 | |
| 15)Kurita et al. GLI3-dependent repression of DR4 mediates hedgehog antagonism of TRAIL-induced apoptosis. Oncogene. 2010;29(34):4848-58. PMID: 20562908 | |
| 16)Goda et al. Mechanisms of enhancement of TRAIL tumoricidal activity against human cancer cells of different origin by dipyridamole. Oncogene. 2008 ;27(24):3435-45. PMID: 18193086 | |
| 17)Jeon et al. Ribosomal protein S6 is a selective mediator of TRAIL-apoptotic signaling. Oncogene. 2008;27(31):4344-52. PMID: 18362888 | |
| 18)Wu et al. A new oridonin analog suppresses triple-negative breast cancer cells and tumor growth via the induction of death receptor 5. Cancer Lett. 2016 ;380(2):393-402. PMID: 27387452 | |
| 19)Qian et al. Co-inhibition of BET and proteasome enhances ER stress and Bim-dependent apoptosis with augmented cancer therapeutic efficacy. Cancer Lett. 2018;435:44-54. PMID: 30059709 | |
| 20)Li et al. The HECTD3 E3 ubiquitin ligase facilitates cancer cell survival by promoting K63-linked polyubiquitination of caspase-8. Cell Death Dis. 2013;4:e935. PMID: 24287696 |
ANTIBODIES FOR RESEARCH USE ONLY.
For additional information, visit ProSci's Terms & Conditions Page.
